These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 4580632)

  • 21. The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass.
    Kunz SA; Miles LF; Ianno DJ; Mirowska-Allen KL; Matalanis G; Bellomo R; Seevanayagam S
    Perfusion; 2018 Sep; 33(6):445-452. PubMed ID: 29544405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparin.
    Vanpee D; Gillet JB; Swine C
    Ann Emerg Med; 2000 Sep; 36(3):277-8. PubMed ID: 10969239
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anticoagulant therapy].
    Sagault P
    Soins; 1978 Nov; 23(22):29-34. PubMed ID: 252177
    [No Abstract]   [Full Text] [Related]  

  • 25. Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks?
    Douketis JD; Spyropoulos AC
    J Thromb Haemost; 2010 Mar; 8(3):496-8. PubMed ID: 20040039
    [No Abstract]   [Full Text] [Related]  

  • 26. Standardization of laboratory tests for controlling anticoagulent therapy.
    Zucker S; Cathey MH; Sox PJ; Hall EC
    Am J Clin Pathol; 1970 Mar; 53(3):348-54. PubMed ID: 5416772
    [No Abstract]   [Full Text] [Related]  

  • 27. [Conditions of resistance to vitamin K antagonists].
    Marchal G; Samama M; Charon P
    Sem Ther; 1964 Dec; 40(10):623-7. PubMed ID: 5878936
    [No Abstract]   [Full Text] [Related]  

  • 28. Hemostasis.
    Breckenridge RT
    Surg Annu; 1973; 5():145-55. PubMed ID: 4602213
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.
    Pychyńska-Pokorska M; Pągowska-Klimek I; Krajewski W; Moll JJ
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):987-94. PubMed ID: 21835642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
    Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
    J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On the therapy of bleeding tendency due to vitamin K deficiency and dysfunction of the liver during the first year of life. (Combined treatment with a concentrate of factors II, VII, IX and X and heparin) (author's transl)].
    Göbel U; Petrich C
    Monatsschr Kinderheilkd (1902); 1974 Feb; 122(2):60-4. PubMed ID: 4594807
    [No Abstract]   [Full Text] [Related]  

  • 32. Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects.
    Ogston D; Douglas AS
    Drugs; 1971; 1(3):228-46. PubMed ID: 4256645
    [No Abstract]   [Full Text] [Related]  

  • 33. BLEEDING TENDENCIES IN THE SURGICAL PATIENT: THEIR DETECTION AND CORRECTION.
    OLWIN JH; KOPPEL JL
    Surg Clin North Am; 1964 Feb; 44():185-94. PubMed ID: 14116103
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized, controlled trial of individualized heparin and protamine management in infants undergoing cardiac surgery with cardiopulmonary bypass.
    Gruenwald CE; Manlhiot C; Chan AK; Crawford-Lean L; Foreman C; Holtby HM; Van Arsdell GS; Richards R; Moriarty H; McCrindle BW
    J Am Coll Cardiol; 2010 Nov; 56(22):1794-802. PubMed ID: 21087706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of anticoagulant activity of heparin and low molecular weight heparins by poly-l-lysine: A comparative 'in vitro' study versus protamine sulfate.
    Muralidharan-Chari V; Kim J; Mousa SA
    Thromb Res; 2017 Jul; 155():128-130. PubMed ID: 28538195
    [No Abstract]   [Full Text] [Related]  

  • 36. Anticoagulant therapy: questions and answers.
    Sherry S
    Compr Ther; 1976 Dec; 2(12):58-65. PubMed ID: 1000925
    [No Abstract]   [Full Text] [Related]  

  • 37. [STATUS OF THE BLOOD COAGULATION SYSTEM AND THE USE OF ANTICOAGULANTS IN PATIENTS WITH STRANGULATED HERNIA].
    PAVLOVSKII DP
    Khirurgiia (Mosk); 1964 Feb; 40():145-52. PubMed ID: 14170172
    [No Abstract]   [Full Text] [Related]  

  • 38. [Anticoagulant drugs. Fibrinolytic drugs].
    Cristea E
    Rev Chir Oncol Radiol O R L Oftalmol Stomatol Ser Oftalmol; 1976; 20(2):105-7. PubMed ID: 133400
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticoagulants in pregnancy: a review of indications and complications.
    Hirsh J; Cade JF; Gallus AS
    Am Heart J; 1972 Mar; 83(3):301-5. PubMed ID: 4551025
    [No Abstract]   [Full Text] [Related]  

  • 40. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.